GRDN — Guardian Pharmacy Services, Inc.

Summary of Guardian Pharmacy Services, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $397.6 million, a 17% increase year-over-year, with 12% organic growth.
• Adjusted EBITDA: $39.5 million, up 53% year-over-year, with margins expanding to 9.9%.
• Gross Profit: Increased by 27% to $85.5 million, gross margins improved to 21.5% from 19.8%.
• Cash Flow: Cash balance rose to $66 million, up from $36 million in Q3 2025 and $5 million at the end of 2024.
• Adjusted EPS: $0.37 per share.
• Full-Year 2025 Adjusted EBITDA: $115 million, exceeding guidance of $104 million to $106 million.

2. Strategic Updates and Business Highlights

• Organic Growth: Achieved 13% organic revenue growth driven by new resident additions and increased script volumes.
• Acquisitions: Completed three acquisitions mid-year, contributing to an 18% total revenue growth.
• Clinical Initiatives: Conducted over 100,000 clinical interventions benefiting approximately 74,000 residents, highlighting the company's commitment to medication management and care coordination.
• Vaccine Clinics: Administered over 120,000 vaccines, with profitability improving due to better purchasing and reimbursement strategies.
• Technology Investments: Rolled out new HIPAA-compliant messaging systems to enhance service reliability and workflow efficiency.

3. Forward Guidance and Outlook

• 2026 Adjusted EBITDA Guidance: Raised to $120 million to $124 million, reflecting confidence in continued growth despite industry changes.
• Revenue Forecast for 2026: Maintained at $1.4 billion to $1.42 billion, accounting for new pricing impacts from the Inflation Reduction Act (IRA).
• Long-Term Outlook: Anticipates continued demographic tailwinds as the aging population increases demand for long-term care services.

4. Bad News, Challenges, or Points of Concern

• Impact of the IRA: The IRA introduces operational complexities and pricing pressures that could affect profitability and cash flow.
• Competitive Pressures: Noted a competitor's bankruptcy, which could lead to market disruptions and potential opportunities, but also reflects broader industry challenges.
• Margin Compression: New acquisitions are currently dampening overall margins by approximately 90 basis points, and there are concerns about sustaining favorable payor dynamics.

5. Notable Q&A Insights

• Durability of Vaccine Program: The vaccine program's profitability is expected to remain durable into 2026, contributing positively to margins.
• Acquisition Strategy: The company is actively pursuing M&A opportunities, particularly in light of potential market dislocations due to competitors' struggles.
• Operational Efficiency: Labor efficiencies are primarily driven by scaling existing operations rather than improvements in labor cost inflation.
• Market Dynamics: The company is monitoring the impact of IRA negotiations on profit contributions between generics and branded drugs, aiming to align margins with prescription volume.

Overall, Guardian Pharmacy Services, Inc. reported strong financial results for Q4 2025, with a positive outlook for 2026 despite facing industry challenges related to regulatory changes and competitive pressures.